Want to see HK:2157 full AI Analyst Report?
2157 Stock Chart & Stats
HK$4.98
-HK$0.04(-1.65%)
At close: 4:00 PM EST
HK$4.98
-HK$0.04(-1.65%)
Day’s Range― - ―
52-Week RangeHK$3.55 - HK$10.50
Previous CloseN/A
Volume4.02M
Average Volume (3M)13.90M
Market Cap
HK$7.90B
Enterprise ValueHK$5.96B
Total Cash (Recent Filing)HK$959.17M
Total Debt (Recent Filing)HK$1.06B
Price to Earnings (P/E)27.6
Beta1.04
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,804,439,800
10 Day Avg. Volume11,565,494
30 Day Avg. Volume13,902,953
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.65
Price to Sales (P/S)8.60
P/FCF Ratio-94.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.10Price Target Upside62.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$1.20B
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins (~80%+)Sustained ~80%+ gross margins indicate strong unit economics typical of differentiated biologics/ADC assets. High product margins create durable operating leverage as revenue scales, helping absorb R&D and commercial costs and supporting long-term profitability if sales momentum persists.
2025 Revenue And Profit InflectionA clear 2025 inflection—~30% revenue growth to ~911M with ~28% net margin—signals commercial traction and the ability to convert sales into sustainable profit. This structural improvement improves funding options, partner interest, and capacity to reinvest in the pipeline, reducing execution risk over months.
Diversified Pipeline And Revenue ModelA multi-platform R&D footprint (biologics, ADCs, small molecules) plus commercialization, licensing, and potential contract manufacturing revenues spreads development and commercialization risk. Multiple monetization channels increase resilience and long-term revenue optionality versus single-product peers.
Bears Say
Negative Operating And Free Cash FlowNegative OCF and FCF despite reported 2025 profitability show weak cash conversion and recurring cash burn. That elevates financing and dilution risk, constrains self-funding for trials or commercialization, and limits strategic flexibility absent a sustained improvement in cash generation.
Meaningful Debt BurdenA roughly 1.06B debt load and material leverage reduce financial flexibility and raise refinancing and interest-service risk. For a biotech with uneven cash flow, debt can force trade-offs between servicing creditors and investing in R&D or commercialization, constraining long-term strategic optionality.
Historically Volatile ProfitabilityThe company’s history of large losses through 2021–2024 means the 2025 profit may be cyclical rather than structural. Biotech earnings depend on regulatory and commercial execution; reversion of revenue or margin pressure could quickly reverse gains, keeping execution and sustainability risk elevated.
Lepu Biopharma Co. Ltd. Class H News
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$3.55 and its highest was HK$10.50 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$7.90B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Aug 26, 2026 which is in 50 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Mar 25, 2026. The company reported HK$0.136 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.136.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Undervalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.136 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.204%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.28%
12-Months-Change
Fundamentals
Return on Equity
24.17%
Trailing 12-Months
Asset Growth
43.87%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
2157 Stock 12 Month Forecast
Average Price Target
HK$8.10
▲(62.65% Upside)
Technical Analysis
Genscript Biotech
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---